A Phase I, Randomized, Double-Blind, Placebo-Contralled, Single Asending Dose / Multiple Ascending Dose Study of CS0159 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics, and Effect Food in Healthy Subject
Latest Information Update: 20 Oct 2022
At a glance
- Drugs Linafexor (Primary)
- Indications Primary sclerosing cholangitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Cascade Pharmaceuticals
- 15 Oct 2022 Status changed from recruiting to completed.
- 25 Nov 2021 Status changed from not yet recruiting to recruiting.
- 25 Oct 2021 New trial record